Characteristics of primary Sjögren's syndrome patients
| Primary Sjögren's patients (N=395) | ||
|---|---|---|
| Age (years) | 57.5(46–66) | 55.4±13.7 |
| Sex (female) | 378 (95.7%) | |
| Disease duration (years) | 6 (2–12) | 7.6±6.4 |
| Ocular symptoms | 358 (90.9%) | |
| Oral symptoms | 368 (93.4%) | |
| Objective ocular involvement | 313 (79.48%) | |
| Objective oral involvement | 286 (72.6%) | |
| Positive salivary gland biopsy | 250/259 (96.5%) | |
| Autoantibodies to antiSSA or antiSSB | 317 (80.4%) | |
| Anti-SSA | 313 (79.44%) | |
| Anti-SSB | 202 (51.3%) | |
| Present or past systemic involvement | 251 (63.7%) | |
| Cutaneous | 109 (29.2%) | |
| Articular | 140 (37.4%) | |
| Muscular | 20 (5.0%) | |
| Pulmonary | 58 (14.5%) | |
| Central nervous system | 14 (3.7%) | |
| Peripheral nervous system | 41 (10.4%) | |
| B-cell proliferative disorder | 19 (4.8%) | |
| Present systemic involvement | 145 (36.8%) | |
| Present or past salivary gland swelling | 202 (51.3%) | |
| Present salivary gland swelling | 87 (22.9%) | |
| Current treatment | ||
| Corticosteroids | 96 (24.3%) | |
| Hydroxychloroquine | 115 (29.1%) | |
| Azathioprine | 13 (3.3%) | |
| Methotrexate | 16 (4.1%) | |
| Rituximab | 12 (3.0%) | |
| Other immunosuppressant | 22 (5.6%) | |
| Pilocarpine | 44 (11.1%) | |
| Lacrymal substitute | 305 (77.2%) | |
| Saliva substitute | 132 (33.4%) | |
| Disease activity indexes | ||
| Physician outcome measures | ||
| ESSDAI | 6 (2–12) | 8.6±8.7 |
| SCAI | 7 (5–10) | 8.1±5.5 |
| SSDAI | 1 (0–2) | 1.3±1.0 |
| PhGA | 3 (2–5) | 2.2±3.0 |
| Patient-centred measures | ||
| ESSPRI | 6 (4.3–7.3) | 5.8±2.3 |
| SSI | 4.9 (3.2–6.6) | 4.8±2.3 |
| PROFAD | 4.2 (2.8–5.8) | 4.4±2.2 |
| PGA | 7 (4–8) | 6.1±2.6 |
Results are expressed as median (Inter-quartile range) and mean±SD or number (%).
ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren's Syndrome Patient Reported Index; EULAR, European League Against Rheumatism; PGA, patient global assessment; PROFAD, Profile of Fatigue and Discomfort; SCAI, Sjögren's Systemic Clinical Activity Index; SSA, Sjogren's syndrome A; SSB, Sjogren's syndrome B; SSI, Sicca Symptoms Inventory.